Our portfolio company, VeriSIM Life investigated for Debiopharm a novel drug combination strategy that combines ADCs with current therapies to enhance their effectiveness in reducing tumor burden. Their hybrid AI computational platform, BIOiSIM®, ranked the predicted optimal combinations with regard to efficacy based on our multi-dimensional Translational Index™ technology.
Our mission at Debiopharm is to develop tomorrow’s standard of care for cancer and improve patient quality of life. Accelerating the translation of our research to clinical success is a priority, and our work with VeriSIM Life is focused on this critical objective. With insights from the BIOiSIM platform, we believe our innovative therapies will rapidly move closer to addressing the unmet needs of cancer patients worldwide.
said Dr. Valerie Nicolas, Deputy to the Head of Translational Medicine at Debiopharm
Read the full case study below.